We are deeply impressed by the efficient execution and global vision of Lynk Pharmaceuticals' management team. We are also very optimistic about the future huge market space and the unmet patient needs in the field of autoimmune disease and cancer. We are excited to partner with the Lynk team to accelerate its growth and look forward to more breakthroughs and successes in the future with our innovation capability.
As there are great demands in autoimmune diseases, JAK inhibitor has the potential to be the game changer. Focused on the highly target-selective and tissue-specific JAK inhibitor, Lynk has the ability to develop BIC and FIC. Besides, clinical progress and business cooperation of innovative therapies will be advanced by virtue of rich experience and efficient execution in the field of small molecule drugs.
Decheng Capital continues to be optimistic about the rapid development of the global autoimmune disease therapeutic field and is confident in the technical strength of Lynk Pharma and the years of experience of its founders and senior management team in this area. At present, Lynk Pharma have established numbers of distinctive targeted drug pipelines and have entered clinical trials in multiple indications. We are confident that Lynk Pharma will set sail from China and help cure patients worldwide!
Lynk Pharmaceuticals is one of biotechnology companies I've ever met, which boasts the highest R&D efficiency in novel drugs. Established in four years ago, it has four self-developed drugs entering into clinical trial stage. Moreover, its projects are worthy of credits for the reason that the ongoing pipeline combination balancing between return on investment and risk of failure is established based on unmet medical needs. Besides, Lynk has successfully out-licensed a preclinical candidate to a US company and has bought early-stage innovation of Japan’s top research institute, which embodies its excellent abilities in international business development.